Citi analyst Yigal Nochomovitz raised the firm’s price target on Crispr Therapeutics (CRSP) to $80 from $77 and keeps a Buy rating on the shares. The firm says the company’s Casgevy revenue beat estimates in Q4. It sees Crisper’s clinical and preclinical updates in 2026 driving potential upside in the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- CRISPR Therapeutics: Casgevy Outperformance and 2026 Pipeline Catalysts Drive Raised $80 Target and Buy, High Risk Rating
- Crispr Therapeutics price target raised to $76 from $74 at Chardan
- Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI
- Crispr Therapeutics price target raised to $82 from $80 at Needham
- Crispr Therapeutics price target raised to $45 from $40 at TD Cowen